111 related articles for article (PubMed ID: 22434731)
1. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Yalon M; Rood B; MacDonald TJ; McCowage G; Kane R; Constantini S; Packer RJ
Pediatr Blood Cancer; 2013 Jan; 60(1):71-6. PubMed ID: 22434731
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma.
Bouffet E; Jakacki R; Goldman S; Hargrave D; Hawkins C; Shroff M; Hukin J; Bartels U; Foreman N; Kellie S; Hilden J; Etzl M; Wilson B; Stephens D; Tabori U; Baruchel S
J Clin Oncol; 2012 Apr; 30(12):1358-63. PubMed ID: 22393086
[TBL] [Abstract][Full Text] [Related]
3. A phase 2 feasibility study of sequential, dose intensive chemotherapy to treat progressive low-grade gliomas in children.
Bruggers CS; Greene D
J Pediatr Hematol Oncol; 2007 Sep; 29(9):602-7. PubMed ID: 17805033
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
5. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Johnson BE; Jackman D; Jänne PA
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4628-31. PubMed ID: 17671154
[TBL] [Abstract][Full Text] [Related]
6. Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
Gnekow AK; Kortmann RD; Pietsch T; Emser A
Klin Padiatr; 2004; 216(6):331-42. PubMed ID: 15565548
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.
Morgenstern DA; Marzouki M; Bartels U; Irwin MS; Sholler GL; Gammon J; Yankanah R; Wu B; Samson Y; Baruchel S
Pediatr Blood Cancer; 2014 Jan; 61(1):128-33. PubMed ID: 23956145
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Wen PY; Chang SM; Lamborn KR; Kuhn JG; Norden AD; Cloughesy TF; Robins HI; Lieberman FS; Gilbert MR; Mehta MP; Drappatz J; Groves MD; Santagata S; Ligon AH; Yung WK; Wright JJ; Dancey J; Aldape KD; Prados MD; Ligon KL
Neuro Oncol; 2014 Apr; 16(4):567-78. PubMed ID: 24470557
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
[TBL] [Abstract][Full Text] [Related]
12. Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I/II study by the German Society for Pediatric Oncology and Hematology.
Wagner S; Erdlenbruch B; Längler A; Gnekow A; Kühl J; Albani M; Völpel S; Bucsky P; Emser A; Peters O; Wolff JE
Cancer; 2004 Apr; 100(8):1750-7. PubMed ID: 15073866
[TBL] [Abstract][Full Text] [Related]
13. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Nghiemphu PL; Lai A; Green RM; Reardon DA; Cloughesy T
J Neurooncol; 2012 Nov; 110(2):245-50. PubMed ID: 22918789
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).
Hirte H; Oza A; Swenerton K; Ellard SL; Grimshaw R; Fisher B; Tsao M; Seymour L
Gynecol Oncol; 2010 Sep; 118(3):308-12. PubMed ID: 20646751
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood.
Packer RJ; Lange B; Ater J; Nicholson HS; Allen J; Walker R; Prados M; Jakacki R; Reaman G; Needles MN
J Clin Oncol; 1993 May; 11(5):850-6. PubMed ID: 8487049
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh JJ; Gururangan S; Friedman AH; Desjardins A; Sathornsumetee S; Herndon JE; Dowell JM; McLendon RE; Provenzale JM; Sampson JH; Smith RP; Swaisland AJ; Ochs JS; Lyons P; Tourt-Uhlig S; Bigner DD; Friedman HS; Rich JN
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):860-8. PubMed ID: 16467100
[TBL] [Abstract][Full Text] [Related]
18. Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.
Rusthoven KE; Feigenberg SJ; Raben D; Kane M; Song JI; Nicolaou N; Mehra R; Burtness B; Ridge J; Swing R; Lango M; Cohen R; Jimeno A; Chen C
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1020-5. PubMed ID: 20231078
[TBL] [Abstract][Full Text] [Related]
19. [HIT-LGG: effectiveness of carboplatin-vincristine in progressive low-grade gliomas of childhood--an interim report].
Gnekow AK; Kaatsch P; Kortmann R; Wiestler OD
Klin Padiatr; 2000; 212(4):177-84. PubMed ID: 10994547
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.
Doherty L; Gigas DC; Kesari S; Drappatz J; Kim R; Zimmerman J; Ostrowsky L; Wen PY
Neurology; 2006 Jul; 67(1):156-8. PubMed ID: 16832099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
